Page 3 - Objective Response Rate News Today

Closing of Transaction with Pierre Fabre Laboratories to Expand Global Tab-cel® Partnership Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE...

– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib – – Median...

Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final…

/PRNewswire/ -- Avstera Therapeutics Corp, an oncology-focused biotech dedicated to addressing the large disease burden and significant unmet need of cancer...

Shattuck Labs Inc STTK announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in…

Shattuck Labs Inc (NASDAQ: STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) 

- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance...

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics hereafter) announced that two major clinical updates...

MARSEILLE, France--(BUSINESS WIRE)--Nov 3, 2023--

Innate Pharma SA announced that several abstracts, including one oral presentation, have been selected for the 65th ASH Annual Meeting and Exposition, taking place December 9-12, 2023 in San Diego,...